Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of “Hold” from Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average rating of “Hold” from the eleven ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $81.09.

HSIC has been the topic of several research reports. Piper Sandler lifted their price objective on Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Monday, February 26th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. Jefferies Financial Group lifted their price objective on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, March 6th. Barrington Research lifted their price objective on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Finally, TheStreet raised Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th.

Henry Schein Stock Down 1.4 %

NASDAQ HSIC opened at $70.20 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The stock has a market capitalization of $9.02 billion, a PE ratio of 22.29, a PEG ratio of 1.75 and a beta of 0.87. Henry Schein has a 1 year low of $60.01 and a 1 year high of $85.39. The business’s 50-day moving average is $74.53 and its 200 day moving average is $72.50.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.04). The business had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.21 earnings per share. Sell-side analysts forecast that Henry Schein will post 5.07 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now owns 209,562 shares of the company’s stock, valued at approximately $15,585,125.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Henry Schein by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 15,331,533 shares of the company’s stock worth $1,336,756,000 after buying an additional 214,846 shares during the period. JPMorgan Chase & Co. boosted its holdings in Henry Schein by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock worth $353,898,000 after buying an additional 53,506 shares during the period. American Century Companies Inc. boosted its holdings in Henry Schein by 7.3% in the 3rd quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock worth $350,392,000 after buying an additional 322,649 shares during the period. Boston Partners boosted its holdings in Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after buying an additional 1,556,831 shares during the period. Finally, Morgan Stanley boosted its holdings in Henry Schein by 143.4% in the 4th quarter. Morgan Stanley now owns 2,337,890 shares of the company’s stock worth $186,727,000 after buying an additional 1,377,207 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.